Frankfurt
21.10.26 | 20:16
61,50 Euro
+0,82 % +0,50
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 61,00 | 63,00 | 07:58 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| NOVONESIS A/S ADR Aktie jetzt für 0€ handeln | |||||
| Mo | Novonesis (Novozymes A/S): Transactions under Novonesis' share buyback program | 14 | GlobeNewswire (USA) | ||
| 15.10. | Novonesis Opens Doors to Students to Inspire the Next Generation of U.S. Biomanufacturing Talent | 4 | GlobeNewswire (USA) | ||
| 12.10. | Novonesis (Novozymes A/S): Transactions under Novonesis' share buyback program | 2 | GlobeNewswire (USA) | ||
| 05.10. | Novonesis (Novozymes A/S): Transactions under Novonesis' share buyback program | 8 | GlobeNewswire (USA) | ||
| 01.10. | Novonesis Expands Dairy Cultures Capacity Amid Rising Demand | 3 | ESM Magazine | ||
| 01.10. | Novonesis (Novozymes A/S): Novonesis completes acquisition of MicroBioGen, strengthening its yeast capabilities | 566 | GlobeNewswire (Europe) | Novonesis completes acquisition of MicroBioGen, strengthening its yeast capabilities The acquisition adds advanced yeast-breeding expertise with a proven track record in bioethanol and broader potential... ► Artikel lesen | |
| 28.09. | Novonesis celebrates major expansion of West Allis production facility, strengthening North American dairy innovation and manufacturing | 412 | GlobeNewswire (Europe) | WEST ALLIS, Wis., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Novonesis, a global leader in biosolutions, announced the completion of a major expansion at its West Allis, Wisconsin production facility. The... ► Artikel lesen | |
| 28.09. | Novonesis (Novozymes A/S): Transactions under Novonesis' share buyback program | 2 | GlobeNewswire (USA) | ||
| 21.09. | Novonesis (Novozymes A/S): Transactions under Novonesis' share buyback program | 8 | GlobeNewswire (USA) | ||
| 14.09. | Novonesis (Novozymes A/S): Initiation of Novonesis' share buyback program | 13 | GlobeNewswire (USA) | ||
| 02.09. | Novonesis (Novozymes A/S): Novonesis to build next generation enzyme production facility in India | 634 | GlobeNewswire (Europe) | Novonesis will invest €600 million to expand its site in?Patalganga?and build?a state-of-the-art?facility. This marks another step in the company's long-term growth strategy and continued investment... ► Artikel lesen | |
| 26.08. | Novonesis Expands U.S. Workforce Development Efforts to Build the Next Generation of Biomanufacturing Talent | 8 | GlobeNewswire (USA) | ||
| 25.08. | Novonesis (Novozymes A/S): Trading by management and close relations of management | 5 | GlobeNewswire (USA) | ||
| 24.08. | Johnson & Johnson, Novozymes und mehr Dividenden im global market - Ex-Tag 25.08.2026 | 10 | Wiener Börse | ||
| 20.08. | Novonesis H1 2026 slides: 8% growth drives raised outlook, EUR 1B buyback | 5 | Investing.com | ||
| 20.08. | Novozymes Aktie steigt nach starken Zahlen, Prognoseerhöhung und Milliarden-Rückkaufprogramm | 10 | Investing.com Deutsch | ||
| 20.08. | Novozymes Reports H1 2026 Results: Full Earnings Call Transcript | 3 | Benzinga.com | ||
| 20.08. | Novozymes Q2 revenue up 9.8% Y/Y; raises FY26 organic sales growth outlook, inaugural €1B share buyback plan | 7 | Seeking Alpha | ||
| 20.08. | Novonesis Q2 Profit Rises | 686 | AFX News | BRUSSELS (dpa-AFX) - Novonesis (NVZMF.PK) released earnings for its second quarter that Increases, from the same period last yearThe company's bottom line came in at EUR171.7 million, or EUR0.37... ► Artikel lesen | |
| 19.08. | Novonesis (Novozymes A/S): H1 2026: Novonesis delivered strong 8% organic sales growth and increases full-year outlook | 1.293 | GlobeNewswire (Europe) | COPENHAGEN, Denmark - August 19, 2026. Novonesis delivered strong first half of 2026 at 8% organic sales growth. 2026 outlook: Organic sales growth increased to 7-8% (previously 5-7%), and the adjusted... ► Artikel lesen |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GENMAB | 351,40 | -0,73 % | Morgan Stanley nimmt Genmab mit "Equalweight" in die Beobachtung auf - Kursziel 42 USD | ||
| INSMED | 83,50 | -0,30 % | Insmed Appoints Former Sanofi CEO Paul Hudson And Verily CFO Utpal Koppikar To Board | ||
| QIAGEN | 42,820 | -0,02 % | Finanzinvestor EQT will Qiagen für über 9 Milliarden Euro kaufen - Agentur | DJ Finanzinvestor EQT will Qiagen für über 9 Milliarden Euro kaufen - Agentur
DOW JONES--Der Finanzinvestor EQT will einem Agenturbericht zufolge den Diagnostikspezialisten Qiagen übernehmen. Wie... ► Artikel lesen | |
| DISC MEDICINE | 75,94 | -0,08 % | Jefferies raises Disc Medicine stock price target on drug opportunity | ||
| ENLIVEN THERAPEUTICS | 41,820 | 0,00 % | H.C. Wainwright hebt Kursziel für Enliven Therapeutics auf 73 $ an | ||
| CG ONCOLOGY | 62,24 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| TANGO THERAPEUTICS | 26,990 | +0,04 % | Tango Therapeutics (TNGX) Has Striking Pancreatic Cancer Data. How Much Is Priced In? | ||
| PRAXIS PRECISION MEDICINES | 256,86 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| BEAM THERAPEUTICS | 24,840 | 0,00 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen | |
| ABSCI | 10,040 | 0,00 % | Absci Corporation: Absci Announces Preliminary Details for Phase 2 STORYLINE Trial of AI-Designed Antibody ABS-201 for Endometriosis | Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial... ► Artikel lesen | |
| NURIX THERAPEUTICS | 26,000 | -0,08 % | H.C. Wainwright raises Nurix stock price target on strong revenue | ||
| SUMMIT THERAPEUTICS | 15,825 | -0,03 % | Akeso, Inc.: Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer | Becomes the 7th International Registrational Clinical Trial for Ivonescimab
Clinical Trial Site Activations in the United States Expected to Begin Q4 2026
HONG... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 19,120 | 0,00 % | ArriVent BioPharma, Inc. - 8-K, Current Report | ||
| RAPPORT THERAPEUTICS | 25,060 | 0,00 % | Jones Trading raises Rapport Therapeutics price target on RAP-219 trial wins | ||
| ARCUS BIOSCIENCES | 19,080 | -0,03 % | Arcus Biosciences prices $250 million stock offering at $17.50 |
NOVONESIS A/S ADR gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 61,50 Euro und damit +0,82 % im Plus. Beim derzeitigen Kurs ergibt sich, basierend auf einer gesamten Ausschüttung von 0,00 Euro in den vergangenen 12 Monaten, eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NOVONESIS A/S ADR finden Sie auf Wallstreet Online.